Related Experiment Video
Updated: May 8, 2026
07:53
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect
Heshu Sulaiman Rahman1, Abdullah Rasedee, Chee Wun How
1Department of Microbiology and Pathology, Faculty of Veterinary Medicine, University Putra Malaysia, Serdang, Selangor, Malaysia.
International Journal of Nanomedicine
|August 16, 2013
Summary
Zerumbone was successfully encapsulated into nanostructured lipid carriers (ZER-NLC) for leukemia treatment. These ZER-NLC show potential as a sustained-release drug delivery system, demonstrating comparable efficacy to free zerumbone in Jurkat cells.
Area of Science:
- Nanotechnology
- Pharmacology
- Materials Science
Background:
- Zerumbone, a lipophilic natural compound, exhibits low water solubility, limiting its therapeutic applications.
- Developing effective drug delivery systems is crucial for enhancing the bioavailability and efficacy of poorly soluble compounds like zerumbone.
- Leukemia treatment necessitates innovative drug delivery strategies for improved patient outcomes.
Purpose of the Study:
- To formulate and characterize zerumbone-loaded nanostructured lipid carriers (ZER-NLC) for potential leukemia therapy.
- To evaluate the physicochemical properties, in vitro drug release, and cytotoxic effects of ZER-NLC.
- To investigate the potential of ZER-NLC as a sustained-release drug carrier system.
Main Methods:
- Zerumbone was loaded into nanostructured lipid carriers using hot, high-pressure homogenization.
- Physicochemical characterization included particle size, polydispersity index, zeta potential, entrapment efficiency, and drug loading.
- In vitro drug release studies and cytotoxicity assays (MTT) were performed on Jurkat cells.
Main Results:
- ZER-NLC exhibited favorable characteristics: spherical shape, average size of 52.68 nm, polydispersity index of 0.29, zeta potential of -25.03 mV, 99.03% entrapment efficiency, and 7.92% drug loading.
- In vitro release showed 46.7% zerumbone release from ZER-NLC over 48 hours, indicating sustained release compared to pure zerumbone (90.5%).
- The half maximal inhibitory concentration (IC50) of ZER-NLC (5.64 μg/mL) was comparable to free zerumbone (5.39 μg/mL) against Jurkat cells.
Conclusions:
- ZER-NLC were successfully prepared and characterized, demonstrating excellent encapsulation efficiency and sustained drug release.
- The comparable cytotoxicity of ZER-NLC to free zerumbone suggests effective delivery and therapeutic potential.
- ZER-NLC represent a promising nanocarrier system for sustained delivery of zerumbone in leukemia treatment.
